InsidersTradesSigma
Follow the Verrica Pharmaceuticals Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Verrica Pharmaceuticals Inc. has logged 69 insider filings. Market capitalisation: €80.4m. The latest transaction was disclosed on 18 August 2026 (Acquisition). Among the most active insiders: Hayes Christopher G.. All data is free.
69
Insider Decl.
n/a
Thresholds
€25m
30 ops.
Buy Volume
€1m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Verrica Pharmaceuticals Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$14.80.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,567 of 29,055 companies
29.9
score / 100
Value11
Quality49
FCF yld-19%
Earn yld-19%
EV/EBITDA·
ROE·
Gross mgn90%
Net mgn-50%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations69 total
20,000 shares@ US$5.06Common StockSEC:0002043558-26-000005:0
Canonical exit: 12 Nov 2026 (T+90)
5,000 shares@ US$4.91Common StockSEC:0002043558-26-000005:1
Canonical exit: 15 Nov 2026 (T+90)
4,200 shares@ US$4.91Common StockSEC:0001579649-26-000005:0
Canonical exit: 15 Nov 2026 (T+90)
2,030 shares@ US$4.92Common StockSEC:0001579649-26-000005:1
Canonical exit: 16 Nov 2026 (T+90)
6,000 shares@ US$4.98Common StockSEC:0002046750-26-000004:0
Canonical exit: 15 Nov 2026 (T+90)
5,000 shares@ US$4.930.030% mcap62.0% of flowCommon StockSEC:0001556327-26-000003:0
Canonical exit: 16 Nov 2026 (T+90)
10,000 shares0Common StockSEC:0001556327-25-000006:0
94,311 shares@ US$4.2425100.0% of flowCommon StockSEC:0002043558-25-000003:0
Canonical exit: 23 Feb 2026 (T+90)
3,536 shares@ US$4.2425100.0% of flowCommon StockSEC:0001556327-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
1,375,380 shares@ US$4.242531.7% of flowCommon StockSEC:0001494695-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
10,000 shares@ US$4.2425100.0% of flowCommon StockSEC:0002046750-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
2,357 shares@ US$4.2425100.0% of flowCommon StockSEC:0001579649-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
4,315 shares@ US$0.650.8% of flowCommon StockSEC:0001415889-25-008505:0
125,000 shares0Common StockSEC:0001415889-25-003233:0
150,000 shares0Common StockSEC:0001415889-25-003232:0
50,000 shares0Common StockSEC:0001415889-25-003234:0
125,000 shares0Common StockSEC:0001415889-25-003230:0
18,426,966 sharesCommon StockSEC:0001415889-24-027709:0
Canonical exit: 20 Feb 2025 (T+90)
280,898 sharesCommon StockSEC:0001415889-24-027711:0
Canonical exit: 20 Feb 2025 (T+90)
1,123,595 sharesCommon StockSEC:0001415889-24-027710:0
Canonical exit: 20 Feb 2025 (T+90)
54,267 shares0Common StockSEC:0001415889-24-026290:0
2,675,611.25 shares0Common StockSEC:0001415889-24-023835:0
9,888 shares@ US$2.6611.3% of flowCommon StockSEC:0001415889-24-022426:0
24,709 shares@ US$2.6613.1% of flowCommon StockSEC:0001415889-24-022425:0
25 of 69 declarations
关于 Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc.是一家美国皮肤病学治疗公司，在美国NASDAQ上市，股票代码为VRCA。公司成立于2013年，总部位于宾夕法尼亚州西切斯特，专注于需要医学干预的皮肤病处方治疗。其定位高度专业化，是医学皮肤病学领域的利基参与者，而非广泛型制药公司。 Verrica的核心业务围绕其主要上市产品YCANTH®（VP-102）展开。YCANTH是一种专有的药物-器械组合产品，含有斑蝥素，通过单次使用的涂抹器设计用于精确的局部给药。公司声称YCANTH是首个也是唯一获得FDA批准的医疗专业人士给药治疗成人和2岁及以上儿童患者传染性软疣的治疗方法。该批准为Verrica在选择有限的获批选项的市场中提供了重要的商业和监管立足点。 除传染性软疣外，Verrica正在开发YCANTH/VP-102用于寻常疣治疗，这是一个更大的皮肤病学细分市场，具有重大的未满足需求。公司一直在与Torii Pharmaceutical推进寻常疣的全球第3期项目，这也反映了其国际开发和合作伙伴战略。Verrica还在推进VP-315的开发，这是一种溶瘤肽，正在评估其在皮肤肿瘤学应用中的作用，包括基底细胞癌。该管线扩展了公司的机会范围，超越了单一商业产品，使其能够接触第二个高价值皮肤病学业务。 从竞争角度来看，Verrica占据了一个专注的专业利基市场。其差异化来自FDA批准的产品地位、支持设备的给药系统以及针对当前治疗标准不完全令人满意的适应症的管线。与此同时，公司在具有挑战性的小型生物技术环境中运营，其中执行风险、制造质量控制、报销动态和商业化效率可能会对业绩产生重大影响。 最近的发展很重要。2026年2月，Verrica任命了新的首席商务官，强调了管理层对扩大YCANTH可及性和加强商业执行的关注。公司还报告了VP-315的新临床和监管进展，以及其寻常疣第3期项目的持续推进。对于投资者而言，VRCA仍然是一个高风险、高上升空间的皮肤病学名称，其投资论点取决于在美国的商业牵引力、潜在的国际扩张以及持续的管线验证。
